|
February 28, 2013
APIM Therapeutics
will be presenting an abstract entitled "Targeting DNA repair mechanisms
increases efficiency of intravesical chemotherapy in an orthotopic rat
bladder cancer model" at the
28th Annual European Urology Association Meeting held in Milan in March
15-19, 2013.
February 27, 2013
APIM Therapeutics
appoints Professor Per Uno Malmström (Department of Urology, Uppsala
University, Sweden) at its scientific advisory board. Prof. Malmström, a
recognized Key Opinion Leader in bladder cancer and Chairman of the
Nordic Bladder Cancer Group, is expected to catalyze future clinical
development of APIM Therepeutics's lead compound ATX-101 having
significant experience in early phase I/II clinical trials for this
indication. For more information, please see
About Us.
February 18, 2013
APIM Therapeutics has
been selected to present at the
6th ANNUAL EUROPEAN LIFE SCIENCE CEO FORUM PARTNERING & INVESTING
in Biotech & Pharma Industry. The conference, which takes place
in March 5-6, 2013 in Zurich, brings together together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.
January 23, 2013
Kostas Alevizopoulos, APIM Therapeutics's Chief Executive Officer gives an interview to
Finance Monthly,
an electronic journal focusing on private equity, acquisitions, funding
and investments. A copy of the article is available
at this address
(see page 32). November 21, 2012
NTNU Professor Marit Otterlei, APIM Therapeutics's Chief Scientific Officer and primary inventor
gives an interview to Norwegian daily journal
Sunnmørsposten about
APIM's anti-cancer development program. A copy of the article (in
Norwegian) is available
at this address. November 14, 2012
Professor M. Otterlei, APIM Therapeutics's Chief Scientific Officer and primary inventor, and her collaborators at the Norwegian University of Science and Technology
(NTNU) publish a scientific paper at
PLOS One showing functional implication of XPA and PCNA
in Nucleotide Excision Repair (NER) mechanisms associated with the replisome. The publication provides
validation of the APIM motif, a newly identified AlkB homolog 2 PCNA interacting
motif mediating interactions of a large number of proteins involved in
DNA repair, cell cycle control and apoptosis with PCNA upon stress. A
full copy of the article can be downloaded
here.
November 9, 2012
Daily Norwegian journal Adressa
interviews NTNU Professor and Chief Scientific Officer of APIM Therapeutics, M. Otterlei, about the promising anti-cancer properties of APIM's drug candidates. A copy of the article (in Norwegian) is available
at this address. October 17, 2012
APIM Therapeutics announced today conclusion of a financing round led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia
Seed, Birk Venture and Ro Invest. Financing will be used to
further advance the preclinical development of APIM Therapeutics'
anti-cancer lead compound ATX-101. For more information, please visit the following
web site link: http://www.prnewswire.com/news-releases/apim-therapeutics-closes-a-financing-round-174553791.html.
August 16, 2012
APIM Therapeutics has
been selected to present at the
12th Biotech In
Europe Investor Forum. The conference, which takes place
in October 1-2, 2012 in Zurich, brings together venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.
April 23, 2012
Biocentury, a leading biotechnology publication, features APIM Therapeutics in an article published on-line on April 23rd. The article discusses in detail the novel therapeutic approach of the company and its implications for the development of novel cancer therapies. A
full copy of the article can be downloaded
here. March 15, 2012
APIM Therapeutics will
present a poster entitled "A novel APIM-motif comprising peptide drug
potentiates the action of several chemotherapeutic drugs by blocking the
interaction between PCNA and key proteins involved in DNA repair, apoptosis
and cell cycle control" at the Annual Meeting
of the American Cancer Association (AACR), taking place in Chicago, USA
(March 31- April 4). The poster (#4676) will be presented on Tuesday, April
03, at the poster session 30, Hall F, 1:00 pm - 5:00 pm. February 6, 2012
APIM Therapeutics has
been selected to present at the
5th Annual European Life Science CEO Forum For Partnering & Investing. The conference, which takes place
in March 6-7, 2012 in Zurich, will focus on executive-level networking, deal-making and partnering
in the Life Science and Biotech Industries. February 1, 2012
APIM
Therapeutics joins the Oslo Cancer
Cluster, an oncology research cluster comprising academic institutions,
biotech and pharma companies, support groups, financial institutions and
regional development players in the field of cancer R & D.
January 5, 2012
A panel of industry experts has selected APIM Therapeutics to present at
BIO-Europe Spring 2012, the springtime counterpart to BIO-Europe. The conference, which takes place
in March 19–21, 2012 in Amsterdam, focuses on biotechnology companies interested in partnering their technologies or products, initiating strategic alliances, or tapping into the international financing network.
November 21, 2011
Biotech Finances, a
French electronic magazine specializing in reporting global biotech
financing news publishes article on APIM Therapeutics (Issue 527, November
21; see
www.biotech-finances.com). A copy of the article (in French) can be
downloaded
here. November 10, 2011
APIM Therapeutics announced today conclusion of a third seed follow-up financing round
led by Scandinavian investment companies Birk Venture and Ro Invest in
syndication with Sarsia Seed, a seed stage investor that has already led two
investment transactions in APIM Therapeutics. Financing will be used to
further advance the preclinical development of APIM Therapeutics'
anti-cancer lead compound in selected tumor indications including blood
cancer and solid tumors. For more information, please visit the following
web site link:
http://www.prnewswire.co.uk/cgi/news/release?id=339330
March 21, 2011
APIM Therapeutics announced today conclusion of a second seed follow up financing round by Sarsia Seed, a Norwegian seed stage life science fund. Financing will be used to advance the preclinical investigation of APIM Therapeutics' lead compound in further cancer in vivo studies, predominantly in Myeloma and Acute Myeloid Leukemia.
For more information, please visit: http://www.prnewswire.co.uk/cgi/news/release?id=315415
May 27, 2010
APIM Therapeutics announced today that Sarsia Seed, a Norwegian seed stage life science fund, has invested NOK 3.5 million (€ 440.000) in APIM Therapeutics. The company, a spin-out from the Norwegian University of Science and Technology (NTNU), is developing novel peptide drugs which have the potential to improve clinical outcomes achieved with a large group of existing first line chemotherapeutics.
|
|
APIM Therapeutics AS is a recent spin-off from the Norwegian University of Science and Technology (NTNU).
Visit our About Us page to find out more.
About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see www.ntnu.no.
About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit www.sarsiaseed.com to find out more.
About Birk Venture
Birk Venture is a Scandinavian venture company exclusively focusing on
innovative life science companies. Visit www.birkventure.no to find out more.
About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit www.televenture.no to find out more.
|
|
